| Balance sheet (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 8.52B | 7.62B | 6.90B | 9.88B | 9.80B | 6.84B |
| Short-term investments | 417.00M | 351.00M | 383.00M | 288.00M | 450.00M | 310.00M |
| Receivables | 7.93B | 6.92B | 6.57B | 6.22B | 6.49B | 6.41B |
| Inventory | 6.49B | 6.19B | 6.57B | 6.17B | 5.16B | 5.01B |
| Total current assets | 26.00B | 23.66B | 22.67B | 25.22B | 24.24B | 20.44B |
| Property, plant and equipment | 11.82B | 10.66B | 10.15B | 9.16B | 8.96B | 9.03B |
| Goodwill and intangibles | 29.56B | 29.75B | 32.49B | 33.25B | 35.97B | 38.53B |
| Total assets | 86.71B | 81.41B | 73.21B | 74.44B | 75.20B | 72.55B |
| Total current liabilities | 16.50B | 14.16B | 13.84B | 15.49B | 13.11B | 11.91B |
| Long-term debt | 9.90B | 12.63B | 13.60B | 14.52B | 17.30B | 18.53B |
| Total liabilities | 34.58B | 33.75B | 34.61B | 37.75B | 39.39B | 39.76B |
| Retained earnings | 49.78B | 47.26B | 37.55B | 35.26B | 31.53B | 27.63B |
| Shareholders' equity | 52.13B | 47.66B | 38.60B | 36.69B | 35.80B | 32.78B |
| Total debt | 12.93B | 14.13B | 14.68B | 16.77B | 18.05B | 18.75B |
| Net debt | 4.41B | 6.51B | 7.78B | 6.89B | 8.25B | 11.91B |
From Abbott Laboratories's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.